Novo Nordisk, U.S. Biotech Company Team up to Create Obesity Pills

Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills

Key Takeaways

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

The World's Obesity Problem Continues to Grow

"Obesity in the US could exceed 40% of all adults by 2030..."

In a new strategic movement that consolidates its leadership in the obesity market, Novo Nordisk has announced an agreement for $2.2 billion with the biotechnology company Septerna, based in San Francisco, for the development of anti-obesity pills. According to the original report, this agreement reflects the efforts of the Danish pharmaceutical company to remain a benchmark in this highly competitive market. Through this exclusive collaboration…

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity

Novo to work with Septerna in hunt for oral obesity drugs

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.